Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Development of the TrendBurden Survey: Assessing Perceived Documentation Burden among Health Professionals in the United States
Sloss, Elizabeth A. , Owoyemi, Ayomide , Sidwell, Kathleen, Abdul, Shanawaz, Dawood, Gigi, Allen, Matthew R., Austria, Davis , Chekeni, Faraaz, Corley, Sarah , Grigg, A O, Hartman, Vince , Levy, Deborah R , Marshall, Kyle , Murphy, Judy, Newman, Barry, Phillips, Toni, Smith, Kevin D., Szymanski, James , Mishra, Anup Kumar , Abdul, Shanawaz, Pope, Zachary, Chekeni, Faraaz , Grigg, Aaron, Johnson, Kevin B. , Marshall, Kyle, Murphy, Judy, Rossetti, Sarah Collins

Applied Clinical Informatics | July 17, 2025 | Volume: 16 | Issue: 03 | Pages: 662-675

10.1055/a-2562-0910 | PMID 40669861 Get It

AbstractDocumentation burden contributes to health professional burnout and negatively impacts health professional well-being and patient care quality. Yet, there is a gap in the literature regarding an effective measure to assess the perceived documentation burden of health professionals in a wide range of care settings over time.We developed and administered a pulse survey to trend, with subsequent administrations, the perceived documentation burden of health professionals in all care settings in the United States over time.A multimethods approach was used which included conducting a scoping review of the literature to identify and then curate a set of potential survey items based on scoping review results. Next, a modified Delphi approach was used with clinical informatics experts for consensus-driven item selection and pulse survey development. Finally, we administered the pulse survey nationally using snowball sampling through professional listservs and networks of organizations.The scoping review helped to identify constructs and items to include on the pulse survey. After four iterations of the modified Delphi approach, consensus was reached on five final items for the pulse survey, labeled “TrendBurden.” The first administration of “TrendBurden” was completed by 1,253 healthcare professionals in April 2024. Most respondents (73.26%) disagreed that the time and effort spent documenting patient care is appropriate, with 77.42% reporting finishing work later or needing to work from home due to excessive documentation tasks. Seventy-four point three-eight percent agreed that the effort or time required to complete documentation tasks impedes patient care, and less than one-third (31.76%) agreed that the EHR is easy to use.The “TrendBurden” Pulse Survey was developed through a scoping review of the literature and expert consensus. The resulting five-question pulse survey was administered nationally and provided insight into current perceptions of documentation burden among healthcare professionals.
Prevalence and prognostic role of atrial fibrillation in chronic severe aortic regurgitation
Pugliesi, Giordano Maria , Scott, Christopher G. , Nkomo, Vuyisile T. , Michelena, Héctor I. , Pislaru, Sorin V. , Kane, Garvan C. , Gillam, Linda D. , Pellikka, Patricia A. , Anand, Vidhu , Pugliesi, Giordano M , Sabbah, Michael S. , Nkomo, Vuyisile T , Scott, Christopher , Pellikka, Patricia A , Michelena, Hector I

Heart | July 16, 2025 | Volume: 112 | Issue: 1 | Pages: 46-52

10.1136/heartjnl-2025-325823 | PMID 40670146 Get It

Background Atrial fibrillation (AF) impacts management decisions in valvular heart disease but its significance in patients with chronic aortic regurgitation (AR) is not well established. Objectives To evaluate the prevalence and prognostic role of AF in patients with chronic, haemodynamically significant AR. Methods Adults with chronic ≥moderate-to-severe AR, from March 2004 to April 2019, were retrospectively identified. Those with acute AR, moderate or worse other valve disease or prior valve surgery were excluded. Patients with AF were identified based on 12-lead ECGs, 1-lead ECGs (showing AF for ≥30 s), or episodes recorded by implanted cardiac devices. Primary outcome was all-cause mortality. Cox regression models were used to assess associations with mortality: model 1 adjusted for age, symptoms (New York Heart Association class II–IV), Charlson Comorbidity Index, left ventricle (LV) end-systolic volume index and AF; model 2 added left atrial volume index and model 3 further added systolic pulmonary artery pressure. Results Of the 1006 included patients (age 59±18 years; 822 (82%) men), 446 (46%) had hypertension and 364 (36%) had a bicuspid aortic valve. AF was present in 161 (16%) patients at the time of ≥moderate-to-severe AR diagnosis. During a median follow-up of 1.6 years (IQR 0.2–6.2), AF was associated with an increased mortality risk in univariate and in all three multivariable models (HR 1.61 (95% CI 1.07 to 2.43), HR 2.21 (95% CI 1.31 to 3.72) and HR 2.06 (95% CI 1.21 to 3.52), respectively), including after propensity matching (HR 1.58 (95% CI 1.01 to 2.48)). Conclusions AF is present in one in six patients with chronic≥moderate-to-severe AR and is associated with an increased risk of mortality even after adjusting for measures of LV systolic and diastolic function. There is a need for future prospective studies to validate these findings and evaluate AF as a potential trigger for early surgery.
Monoclonal Anti–Platelet Factor 4 Antibodies in Recurrent Pregnancy Loss
Bavli, Natalie , Kanack, Adam J. , Splinter, Noah P., Mauch, Emily, Kohlhagen, Mindy , Murray, David, Chen, Dong , Pruthi, Rajiv K. , Padmanabhan, Anand , Mauch, Emily E, Ainsworth, Alessandra J. , McBane, Robert D. , Kohlhagen, Mindy C, Padmanabhan, Anand , Nishimura, Yoshito , Sarode, Ravi

New England Journal of Medicine | July 16, 2025 | Volume: 393 | Issue: 3 | Pages: 306-309

10.1056/nejmc2506014 | PMID 40673591 Get It

Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Yadav, Siddhartha , Couch, Fergus J. , Hillman, Sam , Luo, Linlin , Li, Weiyan , Li, Qixin , Hayes, Jennifer Fallas , Xu, Xiaoqing , Couch, Fergus J. , Xu, Xiaoqing , Yadav, Siddhartha , Earla, Jagadeswara Rao

JCO Precision Oncology | July 16, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-24-00814 | PMID 40669020 Get It

PURPOSE Testing for germline BRCA1 and/or BRCA2 mutations (gBRCAm) is recommended for patients with human epidermal growth factor receptor 2–negative (HER2–) breast cancer (BC) to guide treatment selection with poly (ADP-ribose) polymerase inhibitors (PARPis). However, real-world data on germline BRCA1 and/or BRCA2 (gBRCA) testing and PARPi treatment patterns in metastatic BC (mBC) are limited. METHODS Deidentified patient data from adults diagnosed with HER2– mBC between 2014 and 2022 were captured from electronic health records in the US Flatiron Health database. gBRCA testing patterns and prevalence were examined by tumor subtype (hormone receptor–positive [HR+]/triple-negative) and disease stage at diagnosis. Demographic and clinical characteristics were described by receipt of gBRCA testing and PARPi. PARPi treatment patterns were assessed, and real-word overall survival (OS) was estimated in patients with gBRCAm diagnosed with mBC after January 1, 2018. RESULTS Of the 15,006 total patients, 4,654 (31.0%) received a gBRCA test. gBRCA testing rates mostly increased from 2014 to 2022 and were lower in patients with HR+ than triple-negative tumors. Of the patients who underwent gBRCA testing, 337 (7.2%) had gBRCAm. From 2018 to 2022, PARPi was initiated in 94 (45.6%) of 206 patients with gBRCAm. With a median follow-up of 22.8 months across patients with available first-line treatment start dates, real-world OS was numerically longer among 94 patients with gBRCAm who received PARPi (32.3 months [95% CI, 22.7 to 47.4]) than among 99 patients who did not (21.9 months [95% CI, 18.4 to not reached]). CONCLUSION Although gBRCA testing increased over time, testing and PARPi utilization rates remained suboptimal in potentially eligible patients with HER2– mBC. Exploratory analysis showed numerically longer OS in patients who received PARPi. Wider and timelier gBRCA testing is warranted to inform potentially optimal treatment decisions.
Nylon Suture Snare for Intraocular Foreign Body Removal: A Case Series
Krivit, Jenna, Romo, Jorge Andrade, Reiter, Gregor S. , Iezzi, Raymond , Giacalone, Joseph C. , Andrade Romo, Jorge, Krivit, Jenna, Ye, Run Zhou

Retina | July 16, 2025 | Volume: 45 | Issue: 12 | Pages: 2424-2428

10.1097/iae.0000000000004608 | PMID 40668961 Get It

Purpose: To describe an improved snare technique for the removal of an intraocular foreign body (IOFB) from the posterior segment. Methods: The snare is fashioned from a 23 or 25-gauge blunt-tipped cannula, a 5-0 or 6-0 nylon suture, and a cotton-tipped applicator. The snare is introduced through a 23 or 25-gauge vitrectomy port and tightened around the IOFB, maintaining a closed system. The IOFB can be extracted from the eye by pulling the cannula and extending the circumferential sclerotomy. Results: Four cases of IOFBs were treated using the improved nylon suture snare technique. Three of the four were traumatic open-globe injuries with retained IOFB, for which the snare technique was suitable for removal of the object. In the fourth case, the snare technique was used to remove a posteriorly dislocated silicone intraocular lens optic. No cases of postoperative retinal detachments or endophthalmitis were observed. Conclusion: This snare is fashioned from readily available, inexpensive materials and provides a safe and reliable method for IOFB removal through the vitrectomy port. By maintaining a closed system during IOFB mobilization and removal, the view through the cornea remains stable and intraocular pressure remains constant. Moreover, the snare can grasp irregularly shaped or large IOFBs.
Metagenomic Next-generation Sequencing of Cerebrospinal Fluid: First-year Experience at a Tertiary Referral Hospital
Mulett, Sergio Alvarez , Garcia, Sofia Molina , Saleh, Omar Abu , Rodning, Amanda A, Wengenack, Nancy L. , Patel, Robin , Alvarez Mulett, Sergio , Molina Garcia, Sofia , Abu Saleh, Omar , Wolf, Matthew J, Wengenack, Nancy L , Patel, Robin , Wolf, Matthew J, Norgan, Andrew P.

Clinical Infectious Diseases | July 16, 2025 | Volume: 82 | Issue: 5 | Pages: 808-814

10.1093/cid/ciaf390 | PMID 40668900 Get It

Abstract Background Central nervous system (CNS) infections are significant causes of morbidity and mortality, especially when diagnosis is delayed. Traditional cerebrospinal fluid diagnostic methods for CNS infections have limited sensitivity. Metagenomic next-generation sequencing of cerebrospinal fluid (MSCSF) is a newer diagnostic tool capable of detecting a broad range of pathogens in a single assay. Methods This retrospective cohort study evaluated the first-year experience with MSCSF at Mayo Clinic. A total of 422 tests performed during calendar year 2024 on adult patients at Mayo Clinic facilities and those tested through Mayo Clinic Laboratories were analyzed, with a subcohort analysis of the 210 Mayo Clinic patients performed to define patient characteristics associated with positive results and clinical outcomes. Results The sensitivity of MSCSF for detecting neuroinfection in the subcohort was 64%, with 43% of confirmed neuroinfections diagnosed by MSCSF only. Subjects who were immunosuppressed (odds ratio [OR]: 3.5, P = .008) and those with a high pretest probability of CNS infection (OR: 20.1, P < .001) were more likely to have positive results. Also, those who tested positive were more likely to die within the ensuing 30 days than those who tested negative (OR: 5.2, P = .001). Conclusions MSCSF can be a valuable tool for diagnosing CNS infection but should not be used indiscriminately. It appears to be most beneficial when there is a high clinical suspicion of CNS infection and conventional diagnostics, and available molecular tests, yield negative results. Its integration into clinical practice should be guided by diagnostic stewardship to maximize cost-effectiveness and clinical utility.
Pulmonary Surfactant Metabolism Dysfunction-2
Einarsson, Haukur , Lo, Ying‐Chun , Lo, Ying-Chun

American Journal of Respiratory and Critical Care Medicine | July 16, 2025 | Volume: 211 | Issue: 11 | Pages: 2127-2129

10.1164/rccm.202412-2566im | PMID 40668748 Get It

Estimation of benefit to bispecific antibodies in US patients with lymphoma and multiple myeloma
Rios‐Olais, Fausto Alfredo , Hilal, Talal , Hilal, Talal

Blood Advances | July 16, 2025 | Volume: 9 | Issue: 18 | Pages: 4673-4675

10.1182/bloodadvances.2025016176 | PMID 40668669 Get It

Mechanical stretch promotes sustained proliferation and inflammation in developing human airway smooth muscle
Drake, Li Y. , Pfeffer-Kleemann, Daniel , Zhang, Emily , Ngassie, Maunick Lefin Koloko , Pabelick, Christina M. , Prakash, Y. S. , Zhang, Emily Y , Koloko Ngassie, Maunick Lefin , Prakash, Y S , Drake, Li , Pabelick, Christina M

American Journal of Physiology-Lung Cellular and Molecular Physiology | July 16, 2025 | Volume: 329 | Issue: 2 | Pages: L296-L306

10.1152/ajplung.00070.2025 | PMID 40668642 Get It

Mechanical stretch associated with respiratory support can impair airway development and function in neonates, but the mechanisms are not fully understood. Using developing human airway smooth muscle cells exposed to cyclic forces with static stretch to mimic continuous positive airway pressure, we found that stretch dysregulates long-term cell proliferation and inflammatory cytokine production, and mechanosensitive Piezo ion channels may play a role in the proliferation response.
Pathologic Complete Response and Survival in Rectal Cancer
Lie, Jessica J. , Stucky, Chee‐Chee , Brady, Justin T. , Wasif, Nabil , Etzioni, David A. , Mamon, Harvey J. , Bekaii-Saab, Tanios S , Sonbol, Mohamad Bassam , Sugumar, Kavin , Chang, Yu‐Hui , Bekaii‐Saab, Tanios , Fong, Zhi Ven

JAMA Network Open | July 16, 2025 | Volume: 8 | Issue: 7 | Pages: e2521197

10.1001/jamanetworkopen.2025.21197 | PMID 40668580 Get It

Importance Pathologic complete response (pCR) is increasingly used as a surrogate end point for survival in randomized clinical trials (RCTs) in the field of gastrointestinal oncology. Although this approach has been endorsed by the US Food and Drug Administration, it is still novel and incompletely verified. Objective To evaluate the trial-level association between pCR and survival in rectal cancer RCTs examining the effectiveness of neoadjuvant therapy. Data Sources A meta-analysis was conducted to identify eligible RCTs in PubMed, EMBASE, and Cochrane databases published between database inception to January 3, 2024. Study Selection RCTs evaluating neoadjuvant therapies in patients with rectal cancer who underwent subsequent surgical resection and reported pCR, overall survival (OS), and disease-free survival (DFS) were included. Data Extraction and Synthesis Two investigators extracted the data, which were verified by a third author. The risk of bias and the certainty of the evidence were evaluated using the Cochrane Risk of Bias Tool, version 2, and the Grading of Recommendations Assessment, Development, and Evaluation tool, respectively. Adjusted odds and hazard ratios with their 95% CIs were extracted. Weighted linear regression was used to assess the correlation between pCR and both OS and DFS. Main Outcomes and Measures Trial-level correlation between pCR and both OS and DFS. Results Twenty-five RCTs, including 11 882 patients, met the inclusion criteria. On meta-regression analysis, pCR was not correlated with OS (β = 0.37; 95% CI, −0.98 to 1.71; P = .57). Similarly, pCR was not correlated with DFS (β = −0.84; 95% CI, −2.55 to 0.87; P = .32). Two studies (8%) used in the meta-analysis had high risk of bias. On sensitivity analysis excluding these studies, pCR was still not associated with OS or DFS. Subgroup analysis of RCTs using total neoadjuvant therapies was not possible due to limited sample size. Conclusions and Relevance In this systematic review and meta-analysis of RCTs comparing neoadjuvant therapies in rectal cancer, there was no trial-level association between pCR and survival. These results suggest that the use of pCR as a surrogate end point for survival should be reexamined and used more cautiously.